Drugs / Niagen
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT03685253 | Jan 2019 → May 2022 | diabetic polyneuropathy | University of Maryland, Baltimore | Terminated | No outcome recorded Stop: Business |
| Phase 41 trial · 1 missed | ||||||
| Phase 4 | NCT04809974 | Aug 2021 → Oct 2023 | COVID-19, cognitive disorder, post-infectious disorder | Massachusetts General Hospital | Completed | Missed primary |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Niagen | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04809974 ↗ |
| Route | Oral | “60 participants will take Niagen 2000mg in the form of capsules daily.” NCT04809974 ↗ |